Wall Street analysts forecast that K2M Group Holdings, Inc. (NASDAQ:KTWO) will announce earnings per share of ($0.16) for the current quarter, according to Zacks. Two analysts have provided estimates for K2M Group Holdings’ earnings. The highest EPS estimate is ($0.14) and the lowest is ($0.19). K2M Group Holdings posted earnings per share of ($0.19) in the same quarter last year, which would suggest a positive year-over-year growth rate of 15.8%. The firm is expected to announce its next earnings results on Wednesday, November 1st.

On average, analysts expect that K2M Group Holdings will report full-year earnings of ($0.78) per share for the current financial year, with EPS estimates ranging from ($0.83) to ($0.73). For the next year, analysts anticipate that the business will report earnings of ($0.38) per share, with EPS estimates ranging from ($0.52) to ($0.30). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that follow K2M Group Holdings.

K2M Group Holdings (NASDAQ:KTWO) last posted its earnings results on Tuesday, August 1st. The medical device company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.01. K2M Group Holdings had a negative return on equity of 15.45% and a negative net margin of 16.21%. The company had revenue of $65.70 million for the quarter, compared to analyst estimates of $66.26 million. During the same quarter in the previous year, the firm earned ($0.27) earnings per share. The firm’s quarterly revenue was up 11.0% compared to the same quarter last year.

A number of equities research analysts have issued reports on KTWO shares. Oppenheimer Holdings, Inc. set a $29.00 price target on K2M Group Holdings and gave the company a “buy” rating in a research report on Wednesday, August 2nd. Royal Bank Of Canada reaffirmed a “buy” rating and issued a $26.00 price target on shares of K2M Group Holdings in a research report on Friday, September 22nd. Zacks Investment Research raised K2M Group Holdings from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a research report on Wednesday. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $28.00 price target on shares of K2M Group Holdings in a research report on Thursday, September 28th. Finally, JMP Securities reaffirmed an “outperform” rating and issued a $30.00 price target (up previously from $27.00) on shares of K2M Group Holdings in a research report on Wednesday, June 28th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. K2M Group Holdings presently has a consensus rating of “Buy” and a consensus target price of $27.75.

In other news, insider John Philip Md Kostuik sold 1,090 shares of the firm’s stock in a transaction dated Tuesday, August 15th. The stock was sold at an average price of $24.08, for a total transaction of $26,247.20. Following the sale, the insider now owns 201,961 shares of the company’s stock, valued at approximately $4,863,220.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Gregory S. Cole sold 39,357 shares of the firm’s stock in a transaction dated Friday, August 11th. The stock was sold at an average price of $23.37, for a total value of $919,773.09. The disclosure for this sale can be found here. Insiders have sold a total of 44,129 shares of company stock worth $1,033,644 in the last three months. Corporate insiders own 5.80% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the company. BNP Paribas Arbitrage SA raised its position in shares of K2M Group Holdings by 5,175.3% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,484 shares of the medical device company’s stock worth $109,000 after acquiring an additional 4,399 shares in the last quarter. Legal & General Group Plc raised its position in shares of K2M Group Holdings by 9.1% during the 1st quarter. Legal & General Group Plc now owns 6,763 shares of the medical device company’s stock worth $138,000 after acquiring an additional 564 shares in the last quarter. Dorsey & Whitney Trust CO LLC acquired a new stake in shares of K2M Group Holdings during the 2nd quarter worth about $211,000. Trexquant Investment LP acquired a new stake in shares of K2M Group Holdings during the 1st quarter worth about $250,000. Finally, American International Group Inc. raised its position in shares of K2M Group Holdings by 7.1% during the 1st quarter. American International Group Inc. now owns 15,847 shares of the medical device company’s stock worth $325,000 after acquiring an additional 1,047 shares in the last quarter. 97.86% of the stock is currently owned by institutional investors and hedge funds.

K2M Group Holdings (KTWO) traded up 1.84% during trading on Wednesday, reaching $22.66. The company’s stock had a trading volume of 396,569 shares. K2M Group Holdings has a 1-year low of $16.32 and a 1-year high of $25.99. The stock has a 50 day moving average price of $22.36 and a 200 day moving average price of $22.47. The stock’s market capitalization is $980.45 million.

ILLEGAL ACTIVITY NOTICE: “Analysts Expect K2M Group Holdings, Inc. (KTWO) to Post -$0.16 EPS” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at https://www.americanbankingnews.com/2017/10/04/analysts-expect-k2m-group-holdings-inc-ktwo-to-post-0-16-eps.html.

K2M Group Holdings Company Profile

K2M Group Holdings, Inc is a medical device company focused on designing, developing and commercializing spine and minimally invasive technologies and techniques. The Company’s solutions are focused on achieving three-dimensional Total Body Balance. Its spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor.

Get a free copy of the Zacks research report on K2M Group Holdings (KTWO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for K2M Group Holdings (NASDAQ:KTWO)

Receive News & Ratings for K2M Group Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for K2M Group Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.